61 results match your criteria Alezzandrini Syndrome


Acquired disorders with depigmentation: A systematic approach to vitiliginoid conditions.

J Am Acad Dermatol 2018 Sep 17. Epub 2018 Sep 17.

Department of Dermatology and Pediatric Dermatology, Cutaneous Physiopathology and Integrated Center of Metabolomics Research, San Gallicano Dermatologic Institute, IRCCS, Via Elio Chianesi 53, Rome 00144, Italy.

Acquired disorders with depigmentation are commonly encountered by dermatologists and present with a wide differential diagnosis. Vitiligo, the most common disorder of acquired depigmentation, is characterized by well-defined depigmented macules and patches. Other conditions, such as chemical leukoderma, can present with similar findings, and are often easily mistaken for vitiligo. Read More

View Article
September 2018
4 Reads

New Treatment Modalities for Neovascular Age-Related Macular Degeneration.

Asia Pac J Ophthalmol (Phila) 2017 Nov-Dec;6(6):514-519. Epub 2017 Sep 14.

Asociados de Macula Vítreo y Retina de Costa Rica, San José, Costa Rica.

Age-related macular degeneration (AMD) is considered one of the main causes of severe vision loss in older adults. The neovascular form (nAMD) is an advanced stage, which is responsible for the most severe vision loss. Vascular endothelial growth factor (VEGF) is at present the main factor that leads to the development of a neovascular membrane and the increased leakage from the membrane to the retina. Read More

View Article
December 2017
3 Reads

Un-explained visual loss following silicone oil removal: results of the Pan American Collaborative Retina Study (PACORES) Group.

Int J Retina Vitreous 2017 24;3:26. Epub 2017 Jul 24.

Clinica Ricardo Palma, Lima, Peru.

Purpose: To report the incidence and clinical features of patients that experienced un-explained visual loss following silicone oil (SO) removal.

Methods: Multicenter retrospective study of patients that underwent SO removal during 2000-2012. Visual loss of ≥2 lines was considered significant. Read More

View Article
July 2017
3 Reads

Vitiligo: Not Simply a Skin Disease.

Skinmed 2017 1;15(2):125-127. Epub 2017 Apr 1.

Department of Dermatology, Robert Wood Johnson Medical School, Rutgers University, Somerset, NJ.

Melanocytes, the cells responsible for skin pigmentation, are present in other parts of the body, such as the ocular, auditory, nervous, and cardiac systems. Within these systems, their roles serve a different purpose than their classical counterparts in skin as pigment cells. Such roles include cell turnover in retinal pigment epithelium, maintenance of balance and prevention of environmental damage in the auditory neuroepithelium, role-playing as dendritic cells within the leptomeninges, and prevention of oxidative damage in adipose tissue. Read More

View Article
April 2017
5 Reads

INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up.

Retina 2017 Feb;37(2):334-343

*Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; †Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina; ‡Instituto de Cirugia Ocular, San Jose, Costa Rica; §Departamento de Oftalmologia, Instituto da Visão, Universidade Federal de São Paulo, São Paulo, Brazil; ¶Consorcio Hospital, General Universitario de Valencia, Valencia, Spain; **Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina; and ††Instituto Docente de Especialidades Oftalmológicas (IDEO), Maracaibo, Venezuela.

Purpose: To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR).

Methods: Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. Read More

View Article
February 2017
18 Reads

ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.

Retina 2016 Oct;36(10):1913-8

*Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica; †University of Buenos Aires, Argentina; ‡University of Puerto Rico, San Juan, Puerto Rico; §The King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia; ¶Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland; **Retina Department, Ramón y Cajal University Hospital, Madrid, Spain; ††VISSUM Madrid, Madrid, Spain; ‡‡National Ophthalmological Foundation, Rosario University, Bogota, Colombia; §§Centro Caracas Ophthalmologic Clinic, Caracas, Venezuela; ¶¶Conde Valenciana Foundation, Mexico City, Mexico; ***OFTALMOS University of Buenos Aires, Buenos Aires, Argentina; †††La Fe Hospital, University of Valencia, Valencia, Spain; ‡‡‡Ricardo Palma Clinic, Lima, Peru; §§§Association for Blindness Prevention in Mexico, Mexico City, Mexico; ¶¶¶Retina and Vitreous Unit, Department of Ophthalmology, Moises Broggi Hospital, Barcelona, Spain; ****Department of Ophthalmology, Vision Institute, Federal University of Sao Paulo, Sao Paulo, Brazil; ††††University of Colorado, School of Medicine, Denver, Colorado; ‡‡‡‡Department of Ophthalmology, Federal University of Goias, Goiânia, Brazil; and §§§§LV Prasad Eye Institute, Hyderabad, India.

Purpose: To describe the natural history of eyes with symptomatic idiopathic vitreomacular traction (VMT).

Methods: Retrospective multicenter study of 168 eyes with spectral-domain optical coherence tomography (SD-OCT) findings consistent with idiopathic VMT. All eyes were graded according to SD-OCT findings. Read More

View Article
October 2016
24 Reads

Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.

Br J Ophthalmol 2016 Dec 24;100(12):1605-1610. Epub 2016 Feb 24.

Retina Service, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico.

Background/aims: To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB).

Methods: Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1. Read More

View Article
December 2016
2 Reads

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group.

Retina 2016 May;36(5):859-67

*Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD; †The Vitreoretinal and Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia; ‡The Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina; § Instituto de Cirugia Ocular, San Jose, Costa Rica; ¶University of Puerto Rico, San Juan, Puerto Rico; **Hospital La Fe, Universidad de Valencia, Spain; ††Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela; ‡‡OFTALMOS, Universidad de Buenos Aires, Facultad de Medicina, Buenos Aires, Argentina; §§Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico; ¶¶Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil; and ***MACULA D&T Diagnóstico, Tratamiento & Rehabilitación Visual, Lima, Peru.

Purpose: To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).

Methods: Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1. Read More

View Article
May 2016
5 Reads

Outcomes of cataract surgery in diabetic patients: results of the Pan American Collaborative Retina Study Group.

Arq Bras Oftalmol 2014 Nov-Dec;77(6):355-9

Department of Ophthalmology, University and Polytechnic Hospital La Fe, Valencia, Spain.

Purpose: This study was designed to evaluate the visual and anatomical outcomes after cataract surgery in diabetic patients with different intraoperative therapeutic strategies.

Methods: The research design comprised of a multicentric, retrospective, interventional study conducted at 6 centers in Argentina, Brazil, Costa Rica, Puerto Rico, Spain, and Venezuela. We included 138 diabetic patients with at least 6-month follow-up following phacoemulsification and intraocular lens implantation. Read More

View Article
June 2015
3 Reads

Efficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.

Adv Ther 2014 Sep 20;31(9):975-85. Epub 2014 Aug 20.

University of Buenos Aires, Buenos Aires, Argentina,

Introduction: Fixed-combination glaucoma medications are commonly used to achieve target intraocular pressure (IOP) reduction in patients uncontrolled with monotherapy; however, ocular discomfort associated with eye drops can decrease adherence. This study assessed the efficacy and tolerability of twice-daily fixed-combination brinzolamide 1%/timolol 0.5% (BRINZ/TIM-FC) in Latin American patients transitioned from fixed-combination brimonidine 0. Read More

View Article
September 2014
1 Read

Residual internal limiting membrane after epiretinal membrane peeling: results of the Pan-American Collaborative Retina Study Group.

Retina 2013 Nov-Dec;33(10):2026-31

*Fundación Oftalmológica Los Andes, Santiago, Chile; †Instituto de Cirugía Ocular, San José, Costa Rica; ‡Department of Ophthalmology, University of Puerto Rico, San Juan, Puerto Rico; §Department of Ophthalmology, Universidad Austral, Buenos Aires, Argentina; ¶Instituto Oftalmológico de Valencia, Valencia, Spain; **Vitreoretinal Surgery Unit, Brazilian Institute of Fighting Against Blindness, Assis/Presidente Prudente, Sao Paulo, Brazil; ††The King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia; ‡‡Wilmer Eye Institute, The Johns Hopkins University, Baltimore, Maryland; and §§Vitreoretinal Surgery, Universidade Federal de Sao Paulo, Sao Paulo, Brazil.

Purpose: To determine the degree of residual internal limiting membrane (ILM) after idiopathic epiretinal membrane (ERM) peeling and the usefulness of staining with brilliant blue G.

Methods: A prospective, multicenter, observational study of 98 eyes undergoing pars plana vitrectomy and membrane peeling for idiopathic ERM. All eyes underwent core vitrectomy (20, 23, or 25 gauge) followed by intravitreal triamcinolone to verify that the posterior hyaloid had been removed. Read More

View Article
March 2014
50 Reads

Anatomic and visual outcomes of 23-G vitrectomy without scleral buckling for primary rhegmatogenous retinal detachment.

Eur J Ophthalmol 2013 May-Jun;23(3):417-22. Epub 2013 Mar 6.

Department of Ophthalmology, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.

Purpose: To evaluate the anatomic success rate, visual acuity (VA) changes, and complications of 23-G vitrectomy without associated scleral procedures for the treatment of primary rhegmatogenous retinal detachment (PRRD). 


Methods: Patients diagnosed with PRRD were considered for inclusion. Patients with evidence of proliferative vitreoretinopathy or coexisting ocular pathologies were excluded. Read More

View Article
December 2013
1 Read

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.

Retina 2013 Feb;33(2):403-13

Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Purpose: To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.

Methods: Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C). Read More

View Article
February 2013
1 Read

Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.

J Ophthalmol 2011 30;2011:584238. Epub 2011 Mar 30.

Retina and Vitreous Service, Caracas Clinical Opthalmology Center, Caracas 1010, Venezuela.

This paper demonstrates multiple benefits of intravitreal bevacizumab (IVB) on diabetic retinopathy (DR) including diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) at 24 months of followup. This is a retrospective multicenter interventional comparative case series of intravitreal injections of 1.25 or 2. Read More

View Article
July 2011
10 Reads

Endophthalmitis after pars plana vitrectomy: results of the Pan American Collaborative Retina Study Group.

Retina 2011 Apr;31(4):673-8

Instituto de Cirugía Ocular, San José, Costa Rica.

Purpose: To determine the incidence of endophthalmitis after 20-, 23-, and 25-gauge pars plana vitrectomies (PPVs).

Methods: Retrospective comparative case series of consecutive patients who underwent 20-, 23-, or 25-gauge PPV at 11 centers from Latin America between 2005 to 2009. Pars plana vitrectomy cases were identified through a search of the billing records of each institution. Read More

View Article
April 2011
6 Reads

Alezzandrini syndrome.

BMJ Case Rep 2011 Aug 17;2011. Epub 2011 Aug 17.

Department of Medicine, Government Medical College and Hospital, Chandigarh, India.

View Article
August 2011
14 Reads

Alezzandrini syndrome: report of a sixth clinical case.

Authors:
A Andrade M Pithon

Dermatology 2011 Feb 22;222(1):8-9. Epub 2010 Nov 22.

Southwest Bahia University UESB, Bahia, Brazil.

The aim of this article is to describe an additional clinical case of a patient with Alezzandrini syndrome. Clinically the patient presented with unilateral vitiligo on the left cheek, with partial loss of hearing and vision on the same side. Read More

View Article
February 2011
3 Reads

Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months.

Retina 2011 Feb;31(2):353-63

Retina and Vitreous Service, Clínica Oftalmologica Centro Caracas, Caracas, Venezuela.

Background: To evaluate the anatomical and functional outcomes of intravitreal bevacizumab (1.25 or 2.5 mg) in the treatment of inflammatory choroidal neovascularization at 24 months. Read More

View Article
February 2011
7 Reads

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.

Retina 2010 Jul-Aug;30(7):1002-11

Instituto de Cirugia Ocular, San José, Costa Rica.

Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion. Read More

View Article
September 2010
2 Reads

Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture.

Curr Diabetes Rev 2010 Sep;6(5):313-22

Clinica Oftalmologica Centro Caracas, Edif. Centro Caracas PH-1, Av. Panteon, San Bernardino, Caracas 1010, Venezuela.

Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. Read More

View Article
September 2010
12 Reads

Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.

Ophthalmology 2010 Oct 31;117(10):1974-81, 1981.e1. Epub 2010 May 31.

Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela.

Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (IVB) (Avastin; Genentech Inc., San Francisco, CA) (1.25 or 2. Read More

View Article
October 2010
8 Reads

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months.

Retina 2009 Nov-Dec;29(10):1396-403

Instituto de Cirugia Ocular, San José, Costa Rica.

Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity (BCVA) after injecting 1.25 mg or 2.5 mg of bevacizumab as needed in patients with primary macular edema secondary to branch retinal vein occlusion. Read More

View Article
December 2009
1 Read

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

Ophthalmology 2009 Aug 9;116(8):1488-97, 1497.e1. Epub 2009 Jul 9.

Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela.

Purpose: To report the 24-month anatomic and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin; Genentech, Inc., San Francisco, CA; 1.25 or 2. Read More

View Article
August 2009
6 Reads

Vitiligo: a sign of systemic disease.

Indian J Dermatol Venereol Leprol 2006 Jan-Feb;72(1):68-71

Dermatology, New Jersey Medical School, Newark, New Jersey 07103-2714, USA.

Vitiligo reflects a systemic process that has important implications beyond the skin. These include other autoimmune diseases and ocular and neurological abnormalities. Alezzandrini syndrome and Vogt-Koyanagi-Harada syndrome particularly exemplify this relationship. Read More

View Article
June 2006
7 Reads

[Intraocular helminthiasis].

Arch Oftalmol B Aires 1970 Jun;45(6):213-22

View Article

[Macula lutea injuries due to an eclipse].

Arch Oftalmol B Aires 1968 Jun;43(6):146-50

View Article

[Inflammatory pseudotumor of the orbit].

Arch Oftalmol B Aires 1967 Aug;42(8):216-23

View Article

[Melanoma].

Authors:
A A Alezzandrini

Arch Oftalmol B Aires 1967 Apr;42(4):68-72

View Article

[Diktyoma (embryonal medulloepithelioma)].

Arch Oftalmol B Aires 1967 Mar;42(3):29-33

View Article

[Ptosis. (Clinico-surgical criterion)].

Authors:
A A Alezzandrini

Arch Oftalmol B Aires 1967 Jan-Feb;42(1):5-9

View Article
September 1968

[Retinography with fluorescein].

Arch Oftalmol B Aires 1965 Nov;40(11):363-82

View Article
November 1965

[GROENBLAD-STRANDBERG SYNDROME. ITS OCULAR MANIFESTATIONS].

Authors:
A A ALEZZANDRINI

Arch Argent Dermatol 1964 Sep;14:212-7

View Article
September 1964
4 Reads

[OCULAR TOXOPLASMOSIS].

Arch Oftalmol B Aires 1963 Dec;38:407-16

View Article
December 1963

[AMYLOIDOSIS OF THE CONJUNCTIVA].

Arch Oftalmol B Aires 1963 Sep;38:286-91

View Article
September 1963

[HYPHEMAS. ITS CLINICAL FORMS AND TREATMENT].

Authors:
A A ALEZZANDRINI

Arch Oftalmol B Aires 1963 May;38:123-30

View Article

[The Francois dyscephalic syndrome].

Ann Ocul (Paris) 1963 May;196:456-65

View Article
May 1963
7 Reads

[Epitheliomas of the eyelids].

Arch Oftalmol B Aires 1962 Oct;37:268-75

View Article
October 1962